SecBot SecBot

PALI drug pipeline

PALISADE BIO, INC. · 1 rated drug
$1.03
−8.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2b
Time to marketIf Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.

PALI-2108 Updated Nov 10

What to watch

The next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.

Bull case
  • PALI-2108 is a gut-activated PDE4 inhibitor prodrug designed to deliver anti-inflammatory activity locally in the colon while avoiding systemic side effects that have plagued other PDE4 inhibitors like Otezla (apremilast). This differentiated mechanism could offer a better-tolerated oral option in the large IBD market.
  • Phase 1b data showed 100% clinical response in a small UC cohort, favorable safety across 89 subjects, and rapid (within 7 days) localized target engagement with suppression of inflammatory gene programs, supporting the Phase 2 rationale.
  • Analyst consensus is overwhelmingly positive: 10 Buy/Strong Buy vs 1 Hold, with a mean price target of $9.80 (roughly 7x the current ~$1.14 stock price). Firms include Oppenheimer, Stifel, B. Riley, Piper Sandler, and Raymond James.
Bear case
  • PALI-2108 is still in Phase 2b, and the IBD market is crowded with approved biologics (Entyvio, Stelara, Skyrizi) and small molecules (Xeljanz, Rinvoq). Even if Phase 2b succeeds, the drug faces a long, expensive path to approval with high risk of failure.
  • The company is a clinical-stage biotech with no approved products or revenue. It will likely need to raise additional capital through dilutive equity offerings to fund the Phase 2b and Phase 2a trials, which could pressure the stock.
  • Phase 1b data, while showing 100% clinical response in a small UC cohort, came from a tiny sample size (single cohort) and may not replicate in the larger, placebo-controlled Phase 2b trial.